Author - 'Peter Goldberg'

Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today a poster presentation on the safety and efficacy of PRV111 in patients with...

BIO International Convention 2021

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year due to COVID-19, Bio International 2021 was informative and enjoyable. The company connected with potential investors and industry partners in discussing their...

Contact Us
close slider

Contact Us